Grifols is a strong long-term investment due to its leading position in the plasma industry and improving financial fundamentals. Despite short-term volatility and lack of a dividend, its revenue and EBITDA growth, improved leverage ratio, and significant liquidity highlight its resilience and potential for future profitability.